Vor Accumulated Other Comprehensive Income from 2010 to 2025

VOR Stock  USD 0.88  0.07  7.36%   
Vor Biopharma Accumulated Other Comprehensive Income yearly trend continues to be relatively stable with very little volatility. Accumulated Other Comprehensive Income is likely to drop to about -72.8 K. Accumulated Other Comprehensive Income is gains and losses not included in net income that are recorded in shareholders' equity, reflecting changes in the value of assets or liabilities that are not realized. View All Fundamentals
 
Accumulated Other Comprehensive Income  
First Reported
2010-12-31
Previous Quarter
-69.3 K
Current Value
-72.8 K
Quarterly Volatility
82.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vor Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vor Biopharma's main balance sheet or income statement drivers, such as Net Interest Income of 8.6 M, Interest Income of 8.6 M or Depreciation And Amortization of 3.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.1. Vor financial statements analysis is a perfect complement when working with Vor Biopharma Valuation or Volatility modules.
  
Check out the analysis of Vor Biopharma Correlation against competitors.
To learn how to invest in Vor Stock, please use our How to Invest in Vor Biopharma guide.

Latest Vor Biopharma's Accumulated Other Comprehensive Income Growth Pattern

Below is the plot of the Accumulated Other Comprehensive Income of Vor Biopharma over the last few years. It is gains and losses not included in net income that are recorded in shareholders' equity, reflecting changes in the value of assets or liabilities that are not realized. Vor Biopharma's Accumulated Other Comprehensive Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vor Biopharma's overall financial position and show how it may be relating to other accounts over time.
Accumulated Other Comprehensive Income10 Years Trend
Pretty Stable
   Accumulated Other Comprehensive Income   
       Timeline  

Vor Accumulated Other Comprehensive Income Regression Statistics

Arithmetic Mean(30,402,442)
Geometric Mean0.00
Coefficient Of Variation(272.44)
Mean Deviation53,046,890
Median(30,000)
Standard Deviation82,829,744
Sample Variance6860.8T
Range242.6M
R-Value(0.25)
Mean Square Error6903.3T
R-Squared0.06
Significance0.36
Slope(4,292,587)
Total Sum of Squares102911.5T

Vor Accumulated Other Comprehensive Income History

2025-72.8 K
2024-69.3 K
2023-77 K
2022-770 K
2020-242.6 M
2019null

About Vor Biopharma Financial Statements

Vor Biopharma shareholders use historical fundamental indicators, such as Accumulated Other Comprehensive Income, to determine how well the company is positioned to perform in the future. Although Vor Biopharma investors may analyze each financial statement separately, they are all interrelated. The changes in Vor Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Vor Biopharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-69.3 K-72.8 K

Additional Tools for Vor Stock Analysis

When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.